Clinton to drugmakers: Explain your prices; New amicus briefs for Amarin against FDA;

> Former President Bill Clinton had some advice for drugmakers at the BIO meeting Monday: He urged the industry to "explain, explain, explain" the reasons why Americans pay so much more for drugs than other health systems do. Report

> Sanofi ($SNY) won European approval to market Gardasil 9, the new version of the human papillomavirus vaccine the French drugmaker markets along with Merck & Co ($MRK). Report

> Amicus briefs are piling up in Amarin's ($AMRN) lawsuit against the FDA, which claims its off-label marketing plans should be covered by the First Amendment. Report

> Growth in Africa's pharma market makes the continent the only place where genuinely high growth is still achievable, McKinsey analysts say; they predict sales there will climb toward $65 billion by 2020 from $20.8 billion in 2013. Report

And Finally... FitBit's fitness trackers face threats on all sides, but the company can learn some lessons from BlackBerry's ($BBRY) travails. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.